text: <unk>  (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.Seratrodast is currently marketed in Japan,and India(approved in Dec 2012) as an add-on controller therapy in the management of asthma.
  Unlike thromboxane synthase inhibitors, like Ozagrel,<unk>  does not affect thrombus formation, time to occlusion and bleeding time.Seratrodast has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.
option_0: Seratrodast
option_1: Montelukast
option_2: Mizolastine
option_3: Azelastine 
option_4: Pemirolast
option_5: Pranlukast
option_6: Zafirlukast
option_7: Cromolyn 